CD80 and dermatitis: These previously unidentified findings further elaborate the emphasis of cis PD-L1:CD80 interactions on migratory DCs as a primary target for PD-L1 antibodies across several models of skin inflammation, which leads to a significant decrease of CD80, unlike PD-1 antibody therapy (6, 71, 72).